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The repair of peripheral nerve injuries is still one of the most challenging tasks and concerns in
neurosurgery, plastic and orthopedic surgery. Effect of acetyl-L-carnitine (ALC) loaded chitosan conduit
as an in situ delivery system of ALC in bridging the defects was studied using a rat sciatic nerve
regeneration model. A 10-mm sciatic nerve defect was bridged using a chitosan conduit (CHIT/ALC) ﬁlled
with 10 mL ALC (100 ng/mL). In control group (CHIT), the conduit was ﬁlled with the same volume of the
phosphate buffered solution. The regenerated ﬁbers were studied 4, 8, 12 and 16 weeks after surgery. The
functional and electrophysiological studies conﬁrmed faster recovery of the regenerated axons in ALC
treated than control group (P < 0.05). The mean ratios of gastrocnemius muscles weight were measured.
There was statistically signiﬁcant difference between the muscle weight ratios of CHIT/ALC and CHIT
groups (P<0.05). Morphometric indices of regenerated ﬁbers showed number and diameter of the
myelinated ﬁbers in CHIT/ALC were signiﬁcantly higher than in control group. In immuohistochemistry,
the location of reactions to S-100 in CHIT/ALC was clearly more positive than CHIT group. ALC when
loaded in a chitosan conduit resulted in improvement of functional recovery and quantitative
morphometric indices of sciatic nerve.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The repair of peripheral nerve injury is still one of the most
challenging tasks and concerns in neurosurgery, plastic and or-
thopedic surgery. Nerve autograft remains the gold standard;
however, there are several drawbacks such as sacriﬁce of func-
tioning nerves, loss of sensation and mismatch between nerve and
graft [1].
Different graft equivalents have also been applied to bridge the
nerve stump and regulated through the interaction of a variety of
protein and cell signals [2,3].ur).
by Elsevier Ltd. All rights reservedBiodegradable nerve guides as a temporary scaffold are better
than non-degradable biomaterials because the latter remain in situ
as a foreign body and ultimately result in limiting recovery of nerve
function [4]. Nevertheless, the resistance to biodegradation can be a
cause of chronic nerve compression in the long run and a second
surgery may therefore be required for its removal. Beneﬁcial effects
of chitosan as a conduit in promoting nerve regeneration have
already been documented and it seems chitosan as a natural
polymer has excellent properties including biocompatibility,
biodegradability, non-toxicity and adsorption properties, and
might be a suitable functional material for peripheral nerve
regeneration [5,6].
Acetyl-L-carnitine (ALC) is a naturally occurring amino acid
derivative that has both neuroprotective and antinociceptive ef-
fects. Themechanisms of action of ALC are not clear and are likely to
be multifactorial, with effects on circulating neurotrophins and.
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and patient perception of neuropathic symptoms [7]. It has also
essential physiological roles in mitochondrial oxidative energy
metabolism [8].It is a physiological peptide integral to mitochon-
drial aerobic glycolysis [9], and has inherent antioxidant properties
[10], that increases neuronal binding of [11], and responsiveness to
nerve growth factor (NGF) [12,13]. ALC shows a protective and
regenerative action proﬁle on the nervous tissue after traumatic
injuries [14].
Long-term systemic administration of ALC increases the quan-
tity and quality of nerve regeneration after primary nerve repair
[15]. It has been demonstrated that neuroprotective effect of ALC is
dose-dependent [16]. It is not known yet that this effect translates
into increased target organ reinnervation. If so, ALC could offer
great therapeutic potential in case of chronic neuropathies occur-
ring in diseases such as diabetes [17] and HIV disease [18] where
the problem is not merely sensory neuronal death [19,20], but also
the inability of neurons to maintain long peripheral axons and to
regenerate into the target tissues as a result of chronic metabolic
insufﬁciency [18]. Although clinically safe, however, tolerance to
ALC appears to be accompanied with mild, infrequent side effects,
including insomnia, gastric irritation and vomiting, ﬁshy smell of
breath and body odor. A localized, effective and sustained delivery
is crucial for a potentially broader use of ALC and to the best
knowledge of the authors the literature lacks investigation on the
topical effect of ALC on peripheral and it is remained to be studied.
The present study was designed to evaluate effects of ALC
loaded chitosan conduit as an in situ delivery system of ALC in
bridging the defects in rat sciatic nerve transection model.2. Materials and methods
2.1. Experimental design
Eighty male White Wistar rats weighing approximately 290 g
were divided into four experimental groups (n ¼ 20), randomly:
Transected control group (TC), sham-surgery group (Sham), chito-
san control group (CHIT) and ALC group (CHIT/ALC). Each group
was again subdivided into four subgroups of ﬁve animals each and
surveyed in four time points of 4, 8, 12 and 16 weeks. Two weeks
before and during the entire experiments, the animals were housed
in individual plastic cages with an ambient temperature of
23 ± 3 C, stable air humidity, and a natural day/night cycle. The rats
had free access to standard rodent laboratory food and tap water.2.2. Preparation of chitosan conduit
Chitosan solution was prepared by dissolving medium molec-
ular weight, crab shell chitosan (~400 kDa, 85% deacetylated)
(Fluka, SigmaeAldrich St. Louis, MO, USA) in an aqueous solution
(1% v/v) of glacial acetic acid (Merck, Darmstadt, Germany) to a
concentration of 2% (w/v) while stirring on a magnetic stirrer-hot
plate. The solution was stirred with low heat (at 50 C) for 3 h.
The resultant chitosan solution was ﬁltered through a Whatman
No. 3 ﬁlter paper then vacuum ﬁltration to remove any un-
dissolved particles. To overcome the fragility of chitosan, glycerol
(Sigma Chemical Co., St. Louis, MO, USA) was added as 30% (w/w) of
the total solid weight in solution.23 Chitozan conduit was made
according to the method described by others24 by gentle injection
of the prepared solution into a home-made mold. The prepared
conduit was 2 mm in external diameter, 1.8 mm in internal diam-
eter and 10 mm in length. This internal diameter complies with
optimal function in rat models [21].2.3. Grafting procedure
Animals were anesthetized by intraperitoneal administration of
ketamine-xylazine (ketamine hydrochloride 5%, 90 mg/kg and
xylazine hydrochloride 2%, 5 mg/kg). The procedures were carried
out based on the guidelines of the Ethics Committee of the Inter-
national Association for the Study of pain [22]. The University
Research Council approved all experiments.
Following surgical preparation in the sham-operation group
(Sham) the left sciatic nerve was exposed through a gluteal muscle
incision and after careful homeostasis the muscle was sutured with
resorbable 4/0 sutures, and the skin with 3/0 nylon. In the CHIT
group the left sciatic nerve was exposed through a gluteal muscle
incision and transected proximal to the tibio-peroneal bifurcation
where a 7 mm segment was excised, leaving a gap about 10 mm
due to retraction of nerve ends. Proximal and distal stumps were
each inserted 2mm into a chitosan tube and two 10/0 nylon sutures
were placed at each end of the cuff to ﬁx the tube in place and to
leave a 10-mm gap between the stumps. The conduit was ﬁlled
with 10 mL the phosphate buffered saline and sterile Vaseline was
used to seal the ends of the tubes to avoid leakage. In the CHIT/ALC
group the conduit was ﬁlled with 10 mL acetyl e L-carnitine (Sig-
maeAldrich Chemie GmbH, Germany)solution (100 ng/mL) diluted
with normal saline The animals were anesthetized (see above) and
euthanized with transcardial perfusion of a ﬁxative containing 2%
paraformaldehyde and 1% glutaraldehyde buffer (pH 7.4) 4, 8, 12
and 16 weeks after surgery.2.4. Behavioral testing
Functional recovery of the nerve was assessed using the Basso,
Beattie, and Bresnahan (BBB) locomotor rating scale for rat hind
limb motor function [23]. Although BBB is widely used to assess
functional recovery in spinal cord injured animals, however, it has
been demonstrated that it could be most useful in assessment of
never repair processes in peripheral nerve injuries [24]. Scores of
0 and 21 were given when there were no spontaneous movement
and normal movement, respectively. A score of 14 shows full
weight support and complete limbs coordination. BBB recordings
were performed by a trained observer who was blinded to the
experimental design. The testing was performed in a serene envi-
ronment. The animals were observed and assessed within a course
of a 4-min exposure to an open area of a mental circular enclosure.
BBB scores were recorded once before surgery in order to establish
a baseline control and again weekly thereafter to assess functional
recovery during 16 weeks.2.5. Functional assessment of reinnervation
2.5.1. Sciatic functional index (SFI)
Walking track analysis was performed 4, 8, 12 and 16 weeks
after surgery based on Bain et al., 1989 [25]. The lengths of the third
toe to its heel (PL), the ﬁrst to the ﬁfth toe (TS), and the second toe
to the fourth toe (IT) were measured on the experimental side (E)
and the contralateral normal side (N) in each rat. The Sciatic
Function Index (SFI) in each animal was calculated by the following
formula:
SFI ¼ 38:3 ðEPL  NPLÞ=NPL þ 109:5 ðETS NTSÞ=NTS
þ 13:3 ðEITNITÞ=NIT 8:8
In general, the SFI oscillates around 0 for normal nerve function,
whereas around 100 SFI represents total dysfunction. The SFI was
assessed based on the CHIT group and the normal level was
Fig. 1. BBB score for all experimental groups. Lopical administration of ALC with chi-
tosan grafting gave better scores than in CHIT group. Standard error at each data point
is shown with bars.
M.R. Farahpour, S.J. Ghayour / International Journal of Surgery 12 (2014) 1409e1415 1411considered as 0. The SFI was a negative value and a higher SFI
meant the better function of the sciatic nerve.
2.5.2. Static sciatic index (SSI)
SSI is a time-saving digitized static footprint analysis described
by others [26]. A good correlation between the traditional SFI and
the newly developed static sciatic index (SSI) and static toe spread
factor (TSF), respectively, has been reported by others [26]. The SSI
is a time-saving and easy technique for accurate functional
assessment of peripheral nerve regeneration in rats and is calcu-
lated using the static factors, not considering the print length factor
(PL), according to the equation:
SSI ¼ ½ð108:44 TSFÞ þ ð31:85 ITSFÞ  5:49
Where:
TSF ¼ ðETS NTSÞ=NTS
ITSF ¼ ðEIT NITÞ=NIT
Like SFI, an index score of 0 was considered normal and an index
of 100 indicated total impairment.
2.6. Electrophysiological measurement
After 16 weeks, following the track test, all animals were sub-
jected to electrophysiological studies using Nacro bio system
320e3760 A trace 80 (USA). Under general anesthesia the left
sciatic nerve was re-exposed by incision of the skin at the previous
surgical site. Single electrical pulses (at supra maximal intensity)
were delivered via bipolar electrodes placed in turn at the proximal
and distal trunk of the regenerated nerve and electromyography
(EMG) was recorded by inserting an electrode into the belly of
gastrocnemius muscle. The latency and the amplitude of EMGwere
obtained. Also, the difference in latency of EMG was measured, and
the distance between the proximal and distal sites of stimulation
was measured to calculate the conduction velocity across the re-
generated nerve. On the contralateral, right intact side of each
animal, similar measurements were made for the determination of
conduction velocity. The conduction velocity of the bridged nerve
was expressed as a percentage of that on the intact side of each
animal to cancel off variations between animals (% CVR).
The recovery index of EMG amplitude in all groups was calcu-
lated based on Suzuki et al. using the following formula:
Recovery index ¼ Peak amplitude of the operated side/Peak
amplitude of the intact side [27].
2.7. Muscle mass
Recovery assessment was also indexed using the weight ratio of
the gastrocnemius muscles 16 weeks after surgery. Immediately
after sacriﬁcing of animals, gastrocnemius muscles were dissected
and harvested carefully from intact and injured sides and weighed
while still wet, using an electronic balance. All measurements were
made by two independent observers unaware of the analyzed
group.
2.8. Histological preparation and quantitative morphometric
studies
Operated nerve was dissected from surrounding tissues and a
segment including several millimeters proximal and distal to the
graft was harvested. Graft middle cable of Sham, TC, CHIT and CHIT/
ALC groups were ﬁxed in 2.5 percent glutaraldehyde. The grafts
were postﬁxed in OsO4 (2%, 2 h), dehydrated through an ethanolseries and embedded in Epon. Samples were cut in 5 mm, stained
with toluidine blue and examined under light microscopy. Mor-
phometrical analysis was carried out using an image analyzing
software (Image-Pro Express, version 6.0.0.319, Media Cybernetics,
Silver Springs, MD, USA). Equal opportunity, systematic random
sampling and two-dimensional dissector rules were followed in
order to cope with sampling-related, ﬁber-location-related and
ﬁber-size related biases [28].2.9. Immunohistochemical analysis
In this study, anti-S-100 (1:200, DAKO, USA) was used as marker
for myelin sheath. Specimens were postﬁxed with 4% para-
formaldehyde for 2 h and embedded in parafﬁn. Prior to immu-
nohistochemistry nerve sections were dewaxed and rehydrated in
PBS (pH 7.4). Then the nerve sections were incubated with 0.6%
hydrogen peroxide for 30 min. To block non-speciﬁc immuno-
reactions the sections were incubated with normal swine serum
(1:50, DAKO, USA). Sections were then incubated in S-100 protein
antibody solution for 1 h at room temperature. They were washed
three times with PBS and incubated in biotynilated anti-mouse
rabbit IgG solution for 1 h. Horseradish peroxidase-labelled sec-
ondary antibody was applied for 1 h. After that all sections were
incubated with 3,30- diaminobenzidine tetrahydrochloride chro-
mogene substrate solution (DAB, DAKO, USA) for 10 min. The re-
sults of immunohistochemistry were examined under a light
microscope.2.10. Statistical analysis
Experimental results were expressed as means ± SD. Statistical
analyses were performed using PASW 18.0 (SPSS Inc., Chicago, IL,
USA). Model assumptions were evaluated by examining the resid-
ual plot. Results were analyzed using a factorial ANOVA with two
between-subjects factors. Bonferroni test for pairwise comparisons
was used to examine the effect of time and treatments. The dif-
ferences were considered signiﬁcant when P < 0.05.3. Results
3.1. BBB recovery
In order to assess hind limb recovery the open ﬁeld locomotor
was used. Fig. 1 shows BBB scores compared to the baseline. All
experimental groups, except for sham, showed the greatest degree
of functional deﬁcit one week after surgery. The ALC group showed
Fig. 2. Box-and-whisker plots of sciatic nerve function index values in each experi-
mental group during the study period. Topical administration of ALC with chitosan
tube grafting gave better results in functional recovery of the sciatic nerve than in CHIT
group.
Fig. 4. Percentage recovery of conduction velocity in experimental groups. Data are
presented as mean ± SD. *P < 0.05 vs CHIT group.
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compared to the control group during the study period (P < 0.05).
3.2. Recovery of sciatic nerve function and reinnervation
3.2.1. SFI outcome
Fig. 2 shows sciatic function index (SFI) values in experimental
groups. Prior to surgery, SFI values in all groups were near zero.
After the nerve transection, the mean SFI decreased to 100 due to
the complete loss of sciatic nerve function in all animals. Four
weeks after surgery had performed mean SFI was 69.5 ± 2.39 in
CHIT/ALC group, compared to 91.67 ± 3.22 in CHIT group. Eight
weeks after surgery had carried out the improvement in SFI was
observed in animals of CHIT/ALC group (55.3 ± 2.25) that was
signiﬁcantly higher than CHIT (75.2 ± 3.39) animals (P < 0.05).Fig. 3. Bar graph indicating static sciatic index (SSI) values in each experimental group
during the study period. Local administration of ALC with chitosan grafting gave better
results in functional recovery of the sciatic nerve than in CHIT group. Data are pre-
sented as mean ± SD. *P < 0.05 vs CHIT group.After 12 weeks, animals of group CHIT/ALC achieved a mean value
for SFI of 38.4 ± 3.57, whereas in group CHIT, a mean value
of 57.1 ± 4.10 was found. At the end of the study period, 16
weeks after surgery, animals of group CHIT/ALC achieved a mean
value of 29.5 ± 3.75 for SFI of, whereas in group CHIT, a mean
value of 46.3 ± 3.43 was found. The statistical analyses revealed
that the recovery of nerve function was signiﬁcantly faster in CHIT/
ALC than CHIT group (P < 0.05) and, topically administered ALC
promoted functional recovery.
3.2.2. SSI outcome
Changes in SSI were similar to those observed in SFI, indicating
signiﬁcant deﬁcit following the sciatic nerve transection (Fig. 3).
Changes in SSI were signiﬁcant at weeks 4, 8, 12 and 16 weeks of
recovery (P < 0.05). The contrasts indicated SSI values at week 16 to
differ signiﬁcantly from those obtained from control, a trend also
noticed for SFI (P < 0.05).
3.3. Electrophysiology
Figs. 4 and 5 show nerve conduction velocity (NCV) along re-
generated sciatic nerves in experimental groups. NCV in ALC
treated animals was signiﬁcantly higher than that in IOAG group
(P < 0. 05).Fig. 5. Recovery index in experimental groups. Data are presented as mean ± SD.
*P < 0.05 vs CHIT group.
Fig. 6. Gastrocnemius muscle weight measurement. The gastrocnemius muscles of
both sides (operated left and unoperated right) were excised and weighed in the
experimental groups at 16 weeks after surgery. Data are presented as mean ± SD.
*P < 0.05 vs CHIT group.
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The mean ratios of gastrocnemius muscles weight were
measured. There was statistically signiﬁcant difference between
the muscle weight ratios of CHIT/ALC and CHIT groups (P < 0.05).
The results showed that in CHIT/ALC groupmuscle weight ratiowas
bigger than CHIT group and weight loss of the gastrocnemius
muscle was ameliorated by local administration of ALC (Fig. 6).3.5. Morphological ﬁndings
Table 1 shows quantitative morphometric analyses of regener-
ated nerves for each of the experimental groups. 4 weeks after
surgery, CHIT/ALC group presented signiﬁcantly greater nerve ﬁber,
axon diameter and myelin sheath thickness compared to CHIT an-
imals (P < 0.05). Although CHIT presented regeneration patterns,
themorphometric indices in CHIT/ALC group both after 8,12 and 16
weeks were better than CHIT.
Using Factorial ANOVA analysis with two between-subjects
factors (Group  time); in the CHIT/ALC group number of nerve
ﬁbers and myelin thickness did not show signiﬁcant difference
between 8,12 and 16 weeks (P > 0.05). Increase in mean thickness
of myelin sheath did not show statistical difference between 8, 12
and 16 weeks inside each group (P > 0.05). Mean thickness of
myelin sheath from week 8 onward did not show signiﬁcant dif-
ference between CHIT/ALC and Sham group (P > 0.05).Table 1
Morphometric analyses of regenerated nerves for each of the experimental groups: valu
Groups Number of ﬁbers
4 Weeks 8 Weeks 12 Weeks 16 Weeks
Sham 8236 ± 371 8354 ± 430 8435 ± 382 8326 ± 340
TC 0 1155 ± 278 1276 ± 301 3812 ± 243
CHIT 1661 ± 295 3256 ± 259 3788 ± 258 3876 ± 250
CHIT/ALC 3456 ± 224a 4467 ± 230a 6567 ± 271a 6678 ± 256
Groups Diameter of axon (mm)
4 Weeks 8 Weeks 12 Weeks 16 Weeks
Sham 7.04 ± 0.39 6.78 ± 0.35 7.06 ± 0.01 7.02 ± 0.19
TC 0 2.38 ± 0.36 2.44 ± 0.63 3.64 ± 0.47
CHIT 2.65 ± 0.52 4.25 ± 0.44 4.85 ± 0.39 4.89 ± 0.44
CHIT/ALC 4.64 ± 0.47a 5.05 ± 0.58a 6.25 ± 0.41a 7.58 ± 0.39
N: number of ﬁbers D: diameter of ﬁbers (mm) d: diameter of axon (mm) T: thickness of
a Results were signiﬁcantly different from CHIT group (P < 0.05).3.6. Immunohistochemistry
Immunoreactivity to S-100 protein was extensively observed in
the cross sections of regenerated nerve segments. The expression of
S-100 protein signal was located mainly in the myelin sheath. The
axon also showed a weak expression indicating that Schwann cell-
like phenotype existed around the myelinated axons (Fig. 7). In
both groups, the expression of S-100 and the ﬁndings resembled
those of the histological evaluations.
4. Discussion
Restoration of normal neurological function of transected pe-
ripheral nerve remains a great challenge in regenerative medicine
and surgery. Entubulation neurorrhaphy is an excellent alternative
to short interposition nerve grafts [29]. Selection of an appropriate
method to evaluate functional recovery of nerve regeneration is
extremely inﬂuential. Walking is a coordinated activity involving
sensory input, motor response and cortical integration [30].
Therefore, walking track analysis (sciatic function index) is a
comprehensive test. The results of the present study showed that
ALC when loaded in a chitosan tube ended up a faster and signiﬁ-
cant improvement of functional recovery of the sciatic nerve
throughout the study period.
Castaneda et al. [31], suggested that arrival of sprouts from the
proximal stump at the distal nerve stump does not necessarily
imply recovery of nerve function. Walking track analysis has
frequently been used to reliably determine functional recovery
following nerve repair in rat models [25,32]. Our results showed
that moephometric indices were not signiﬁcantly different be-
tween CHIT/ALC and CHIT groups after 8 weeks. In contrary, func-
tional recovery occurred from week 8 to week 16 in CHIT/ALC
supporting again this idea that selection of an appropriate method
to evaluate functional recovery is crucial. This study also supports
the idea that the walking track analysis (SFI) is more comprehen-
sive and reliable than histomorphometric methods in peripheral
nerve repair studies [31,33].
Recording wet muscle weight is a previously utilized alternative
for motor target organ reinnervation [34e37]. In-vitro evidence
suggests that ALC treatment improves the motor neuron activity,
possibly acting as a neurotrophic factor [38], while evidence has
been presented that suggests ALC may enhance functional muscle
recovery in terms of attenuation of muscle atrophy, a reduction of
foot drop, and increased toe spread [14].
Nerve conduction measurement is a direct evidence for the
study of nerve transmission [39].The conduction velocity depends
on the diameter of axons and the thickness of myelin sheath [40].es are given as mean ± SD.
Diameters of ﬁbers (mm)
4 Weeks 8 Weeks 12 Weeks 16 Weeks
12.05 ± 0.19 11.91 ± 0.14 12.03 ± 0.03 12.04 ± 0.05
0 3.92 ± 0.51 4.15 ± 0.28 6.15 ± 0.25
3.64 ± 0.83 8.06 ± 0.5 8.51 ± 0.70 8.95 ± 0.81
a 8.46 ± 0.46a 9.78 ± 0.65a 10.78 ± 0.85a 10.80 ± 0.78a
Thickness of myelin sheath (mm)
4 Weeks 8 Weeks 12 Weeks 16 Weeks
2.57 ± 0.03 2.42 ± 0.01 2.50 ± 0.03 2.53 ± 0.04
0 0.81 ± 0.13 0.83 ± 0.02 1.25 ± 0.03
0.48 ± 0.05 2.03 ± 0.38 2.19 ± 0.29 2.33 ± 0.27
a 1.85 ± 0.06a 2.18 ± 0.27 2.33 ± 0.52 2.55 ± 0.50
myelin sheath (mm).
Fig. 7. Immunohistochemical analysis of the regenerated nerves 16 weeks after surgery from (A) middle cable TC, (B) CHIT, (C) CHIT/ALC and (D) SHAM. There is clearly more
positive staining of the myelin sheath-associated protein S-100 (arrows) within the periphery of nerve, indicating well organized structural nerve reconstruction in ALC treated
nerve compared to that of the CHIT. Scale bar: 10 mm.
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conduction velocity between the ALC treated animals and CHIT
bridged regenerated sciatic nerves, therefore, the CHIT conduit in
combinationwith ALC could be assumed as a safe nerve guide with
no nerve conduction interference.
As the posterior tibial branch of the sciatic nerve regenerates
into the gastrocnemius muscle, it will regain its mass proportional
to the amount of axonal reinnervation [41,42]. In the present study
16 weeks after surgery the muscle mass was found in both exper-
imental groups. However, CHIT/ALC group showed signiﬁcantly
greater ratios of the mean gastrocnemius muscle weight than CHIT
group indicating indirect evidence of successful end organ
reinnervation.
In the histological studies, quantitative morphometrical indices
of regenerated nerve ﬁbers showed signiﬁcant difference between
CHIT and CHIT/ALC groups indicating beneﬁcial effect of topical ALC
on the nerve regeneration.
In immunohistochemistry the expression of axon and myelin
sheath special proteins was evident in both groups which indicate
the normal histological structure. The location of reactions to S-100
in CHIT/ALC group was clearly more positive than CHIT group
further implying that both regenerated axon and Schwann cell-like
cells existed and were accompanied by the process of myelination
and the structural recovery of regenerated nerve ﬁbers.
Beneﬁcial effects of long-term systemic administration of ALC
on the quantity and quality of nerve regeneration have been
documented [15]. It has been suggested that long term use of ALC is
not always well tolerated and infrequently has ended up side ef-
fects, including insomnia, gastric irritation and vomiting and
odorous body [7]. Seeking novel techniques of ALC administration
and to avoid drawback of long-term administration of ALC, we have
shown in this proof of study that topical application of ALC at the
site of transected sciatic nerve could improve functional recovery
and target organ reinnervation in rat.
Neuroprotective properties of systemic ALC have been shown to
persist even when ALC treatment is commenced up to 24 h post
injury [16]. ALC increases the expression and afﬁnity of neuro-
trophin receptors for nerve growth factor (NGF) and it has been
reported that NGF has greatly improved muscle contractility,
muscle weight and histological morphometric tests in neurotised
soleus muscle [34] regarding neuro-trophic role of NGF on sensory
neurons [43]. NGF has also been shown to enhance motor nerve
conduction velocity after sciatic nerve division and repair via a
conduit [44]. While repairing an injured nerve the results of this
study suggests that topical ALC treatment would be of clinical
beneﬁt. It has recently been demonstrated that ALC treatment
virtually eliminates sensory neuronal death after peripheral axot-
omy in vivo [45]. ALC signiﬁcantly enhances the regenerative ca-
pacity of neurons that survive peripheral nerve trauma in addition
to its known neuroprotective effects [46].
However, a topical formulation that provides the same neuro-
trophic stimulus would be ideal because of no long term systemiccomplications and time consuming limitations. Entubulation neu-
rorrhaphy using ALC loaded chitosan tube as an in situ delivery
system of ALC in bridging the defects could be considered as an
excellent alternative to short interposition nerve grafts. The use of a
chitosan tube seems to have several distinct advantages for the
treatment of transected peripheral nerves because it is inert and
does not induce extensive scarring or degeneration after implan-
tation, available and easily performed.
5. Conclusion
In conclusion, this study demonstrated that ALC when loaded in
a chitosan tube improved functional recovery of transected sciatic
nerve in rat. Supported by previous ﬁndings, the results from our
present study would imply that the ﬁnal outcome of both motor
and sensory regeneration and reinnervation following repair of a
peripheral nerve and immediate topical application of ALC may be
of clinical beneﬁt. There are reasonable grounds to believe that this
approach could deliver a superior quality of reinnervation in a
shorter period of time, compared to repair without immediate
topical adjuvant treatment.
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